Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of the 2026 American Heart Association/American College of Cardiology (AHA/ACC) Clinical Categorization System (Categories A-E) for Predicting 30-Day Major Adverse Pulmonary Embolism Events (MAPEE) in Patients Presenting to the Emergency Department With Acute Pulmonary Embolism: A Prospective Observational Cohort Study

NCT07805616 is registered in ClinicalTrials.gov with Marmara University Pendik Training and Research Hospital as lead sponsor.

NCT NCT07805616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07805616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of the 2026 American Heart Association/American College of Cardiology (AHA/ACC) Clinical Categorization System (Categories A-E) for Predicting 30-Day Major Adverse Pulmonary Embolism Events (MAPEE) in Patients Presenting to the Emergency Department With Acute Pulmonary Embolism: A Prospective Observational Cohort Study
Lead sponsor
Marmara University Pendik Training and Research Hospital
Phase
Observational
Overall status
Recruiting
Start date
April 17, 2026
Completion date
March 31, 2027
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute pulmonary embolism, pulmonary embolism, venous thromboembolism